Navigation Links
AMDL CEO Featured in CEOCFO Magazine; Details Progress on DR-70 International Commercialization Strategy & Confidence in FY2009 Financial Forecast

TUSTIN, Calif., June 17 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its Chairman and CEO Mr. Douglas MacLellan has been featured in CEOCFO Magazine - a daily online investment news publication that delivers market news and analysis to investors through exclusive interviews with venture capital and publicly-traded companies listed on US and International stock exchanges.

In his interview Mr. MacLellan comments on AMDL's continued focus to become a leading pharmaceutical company with three distinct and growing divisions that include In Vitro Diagnostics (IVD), High End Skin Care Products, and China-based Pharmaceuticals; and target goals of achieving profitability across AMDL's US and China-based operations by year end.

Mr. MacLellan also provided updates on AMDL's worldwide commercialization strategy for the Company's DR-70 (FDP) IVD cancer test saying, "We are leveraging last year's US FDA approval for DR-70 with the launch of an international commercialization and have already realized sales revenues in this division. I believe in vitro diagnostics will be a substantial segment for the AMDL -- one that absolutely has the potential to generate equivalent or better returns as compared to our China-based pharmaceutical division."

Since 2006 AMDL has achieved more than 100% in year-over-year gross revenue growth and remains on track with its FY2009 business milestones and financial guidance projections. The Company is featured as the "#1 Small-Cap Stock Pick for 2009" by Flaherty Financial News ( ), a New York-based investment newsletter, and was named one of the Top 5 fastest growing publicly-traded companies in Orange County by international consulting group Deloitte.

The CEOCFO interview of Mr. MacLellan has been published and is available upon request by emailing AMDL's Investor Relations at or by visiting the CEOCFO website located at (User subscription is required.) For additional information on AMDL, its portfolio of products and 2009 business strategy visit the Company's website at .

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    (Tel:) 206.310.5323

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
6. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
7. Jenny McCarthy Featured at National Autism Conference in Atlanta, November 9
8. Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer
9. Effective Treatment for Fibromyalgia Featured on Oprah Winfrey Show You Dont Have to Live With That Agony!
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
Post Your Comments:
(Date:11/27/2015)... ... , ... A team of Swiss doctors has released a report on mesothelioma ... posted the findings on the website. Click here to read the details now. ... patients who were treated with chemotherapy followed by EPP surgery. Among the 106 patients ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Lizzie’s Lice Pickers ... company is offering customers 10% off of their purchase of lice treatment product. In ... full price. According to a company spokesperson. “Finding lice is a sure way to ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
Breaking Medicine Technology: